Literature DB >> 19411674

Plasma YKL-40, a new biomarker for atrial fibrillation?

Kristoffer Mads Henningsen1, Susette Krohn Therkelsen, Julia Sidenius Johansen, Helle Bruunsgaard, Jesper Hastrup Svendsen.   

Abstract

AIMS: The aim of this study was to determine changes in a new potential biomarker plasma YKL-40 in patients with atrial fibrillation (AF) before and after electrical cardioversion (CV). METHODS AND
RESULTS: Plasma concentrations of YKL-40 were measured in 56 patients (mean age 65 years, range 34-84) with persistent AF (lasting mean 128 days, range 14-960), in 19 age-matched patients with permanent AF, and in 19 healthy subjects. The patients with persistent AF underwent CV. Plasma YKL-40 was measured prior to CV, and at follow-up after 24 h, 30 and 180 days. Patients with persistent AF had lower plasma YKL-40 than patients with permanent AF [70 microg/L (42-105)] vs. [138 microg/L (48-225)] (P = 0.003), and higher levels than healthy subjects [41 microg/L (29-52)] (P = 0.001). Patients (n = 22) who were still in sinus rhythm (SR) at follow-up 30 days after CV had unchanged plasma YKL-40 compared with baseline levels. The baseline levels of YKL-40 were correlated to the levels of IL-6, but not to high sensitivity C-reactive protein.
CONCLUSION: Patients with AF have significantly elevated levels of YKL-40. YKL-40 was not a significant predictor of successful CV to SR. Plasma levels of YKL-40 did not fall after restoration of SR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411674     DOI: 10.1093/europace/eup103

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  14 in total

1.  Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMI.

Authors:  M Cetin; S A Kocaman; A Canga; A Kırbaş; A Yılmaz; T Erdoğan; O Akgül; Y Uğurlu; M E Durakoğlugil
Journal:  Herz       Date:  2012-09-08       Impact factor: 1.443

Review 2.  Diabetes, Obesity and Atrial Fibrillation: Epidemiology, Mechanisms and Interventions.

Authors:  O Asghar; U Alam; S A Hayat; R Aghamohammadzadeh; A M Heagerty; R A Malik
Journal:  J Atr Fibrillation       Date:  2013-08-31

3.  Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?

Authors:  Gamze Erfan; Savas Guzel; Seref Alpsoy; Emine N Rifaioglu; Sule Kaya; Volkan Kucukyalcın; Birol Topcu; Mustafa Kulac
Journal:  Mol Cell Biochem       Date:  2014-11-25       Impact factor: 3.396

4.  Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation.

Authors:  Kristoffer Mads Henningsen; Brian Nilsson; Julia S Johansen; Xu Chen; Steen Pehrson; Jesper Hastrup Svendsen
Journal:  Inflamm Res       Date:  2009-12-10       Impact factor: 4.575

5.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

6.  A polymorphism associated with increased levels of YKL-40 and the risk of early onset of lone atrial fibrillation.

Authors:  Kristoffer M A Henningsen; Morten S Olesen; Golnaz Sajadieh; Stig Haunsoe; Jesper H Svendsen
Journal:  J Negat Results Biomed       Date:  2013-01-02

7.  Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke.

Authors:  Camilla Noelle Rathcke; Stine Brinkloev Thomsen; Allan Linneberg; Henrik Vestergaard
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

Review 8.  YKL-40--an emerging biomarker in cardiovascular disease and diabetes.

Authors:  Camilla N Rathcke; Henrik Vestergaard
Journal:  Cardiovasc Diabetol       Date:  2009-11-23       Impact factor: 9.951

9.  Hypoadiponectinemia in patients with paroxysmal atrial fibrillation.

Authors:  Byung Joo Choi; Jung Ho Heo; In-Soo Choi; Si-Won Lee; Hyun-Soo Kim; Jae Woo Lee; Tae-Joon Cha
Journal:  Korean Circ J       Date:  2012-10-31       Impact factor: 3.243

Review 10.  Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions.

Authors:  O Asghar; U Alam; S A Hayat; R Aghamohammadzadeh; A M Heagerty; R A Malik
Journal:  Curr Cardiol Rev       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.